Entities / Company
Lexicon Pharmaceuticals.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 35
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Citigroup raised its rating on the stock of Lexicon Pharmaceuticals.Some support3 reports
-
Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.Some support2 reports
-
Artal Group S.A. acquired a significant stake in a company, holding 48% of shares, with BlackRock and other investors also involved.Speculative1 report
-
Lexicon Pharmaceuticals is based in The Woodlands, Texas.Some support3 reports
-
Lexicon Pharmaceuticals presented data at a conference in Berlin in September 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Lexicon Pharmaceuticals this week
News at the entities that move Lexicon Pharmaceuticals most-
Novo Nordisk StructuralBridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Moves Lexicon Pharmaceuticals
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Lexicon Pharmaceuticals
-
Citigroup Mentioned togetherCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves Lexicon Pharmaceuticals
-
New York City Shared contextJoint entities are driving a high volume of General Obligation bond issuance in New York City.Moves Lexicon Pharmaceuticals
-
Texas Shared contextNew World screwworm cases are confirmed in New Mexico and Texas, leading to intensified border surveillance and involving USDA Undersecretary Scott Hutchins.Moves Lexicon Pharmaceuticals
Connections
The 7 strongest of 35, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Craig Granowitz Structural
Craig Granowitz serves as the Chief Medical Officer and senior vice president of Lexicon Pharmaceuticals.
-
Novo Nordisk Structural
Lexicon Pharmaceuticals granted Novo Nordisk an exclusive license for its obesity drug LX9851, which Novo Nordisk develops and commercializes.
-
FDA Structural
FDA regulates Lexicon Pharmaceuticals' drug development, filing, and trial design processes.
-
Citigroup Mentioned together
Citigroup provides financial ratings and analysis on Lexicon Pharmaceuticals' stock.
-
Rachel Martens Structural
Rachel Martens serves as CCO for Lexicon Pharmaceuticals.
-
Texas Shared context
Lexicon Pharmaceuticals is based in Texas.
-
New York City Shared context
Lexicon Pharmaceuticals is observed operating within the context of New York City, specifically at industry conferences and presentations.
History
Events by the month they beganJuly 2026
1 eventJune 2026
6 events- Lexicon Pharmaceuticals partnered with Novo Nordisk on asset LX9851 for optionality.
- Citigroup raised its rating on the stock of Lexicon Pharmaceuticals.
- Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.
- Artal Group S.A. acquired a significant stake in a company, holding 48% of shares, with BlackRock and other investors also involved.
- Lexicon Pharmaceuticals is based in The Woodlands, Texas.
- Lexicon Pharmaceuticals presented data at a conference in Berlin in September 2025.